Navigation Links
Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making three poster presentations at the 46th Annual Meeting of the European Society of Pediatric Endocrinology in Helsinki, Finland June 27 -- 30, 2007 (www.espe2007.org).


The three abstracts feature Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, including a study in juveniles. The Company previously announced that it is preparing for a Phase 3 clinical trial of Generex Oral-lyn in centres in the United States, Europe, and Canada. The abstracts are:

6-Month Study on the Safety and Efficacy of Oral Insulin (Generex Oral-lyn(tm)) Administered at Lunchtime in Juvenile Type-1 DM Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs;

Comparison Of Metabolic Control Of Pre-Prandial S.C. Regular Insulin Versus Prandia Oral Insulin (Generex Oral-lyn(tm)) In Adult Type-1 DM Subjects Maintained on Basal S.C. BID Isophane Insulin (NPH), by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador; and

Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy and a 13-Point Method Designed to Enhance Compliance, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein,
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
Post Your Comments:
(Date:5/16/2008)...0 Demonstrates Statistically Significant Reduction...rvations, - Abstract to be published in 2008 Proce... Clinical Oncology, SAN DIEGO, May 16 /P...Inc. (Amex: ANX ) announced today that, in a regi...demonstrated a statistically significant reduction...
(Date:5/15/2008)... in human clinical data highlight safety profile o...d solid tumors -, BRISBANE, Calif., May 15 /PRNew...iopharmaceutical company developing novel cancer t... lead PARP inhibitor, BSI-201, will,be presented a...nnual,meeting in Chicago., Findings will be prese...
(Date:5/15/2008)...ORTH, N.J., May 15 /- Scher...advancing the science and treatment of,chronic hep...at data from,several clinical studies with PEGINTR...avirin, USP) combination therapy, as well as bocep...ease inhibitor, will be presented at,the 39th annu...
(Date:5/15/2008)...ELL, Switzerland, May 15 /- Ergonex P...and Drug Administration (FDA) has,granted orphan d...pulmonary,arterial hypertension (PAH). Terguride i...hase II trial in Europe., "The FDA,s grant of orp...es and strengthens our development program by offe...
Breaking Medicine Technology:ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Windows Live 24500 000 Donation Commemorates Operation Smiles 25th Anniversary 13896 1Windows Live 24500 000 Donation Commemorates Operation Smiles 25th Anniversary 13896 2The hand cant be fooled study shows 13893 1The hand cant be fooled study shows 13893 2iSOFT Offers Healthcare Single Sign On Solutions After Agreement with Sentillion 13888 1iSOFT Offers Healthcare Single Sign On Solutions After Agreement with Sentillion 13888 2iSOFT Offers Healthcare Single Sign On Solutions After Agreement with Sentillion 13888 3iSOFT Offers Healthcare Single Sign On Solutions After Agreement with Sentillion 13888 4MHA Announces Initial Results of the Specialty Pharmacy Member Profile Initiative 13883 1MHA Announces Initial Results of the Specialty Pharmacy Member Profile Initiative 13883 2MHA Announces Initial Results of the Specialty Pharmacy Member Profile Initiative 13883 3
...WIRE)--May 14, 2007 - BioDelivery,Sciences Interna...tatistically significant results with BEMA Fentany... Phase III efficacy clinical,trial for the product...analysis of the,secondary efficacy endpoints from ...5 (Summary of Pain Intensity Difference at,15 minu...
...market dynamics offers insights into,what will be ...atients, NEW YORK, May 14, 2007 /PRNewswire-USNews...t (TB Alliance), a not-for-profit,product develop...velopment of new TB drugs, today released results ... of the global TB drug market,that offers a detail...
Other Medicine Technology:BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 2BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 3BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 4New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...ct Covers More than 500 Workers, WASHINGTON, May ...dics,and emergency medical technicians in the Grea...a have ratified their first-ever contract as,Teams...ers are now covered by a,strong contract that give...re," said Teamsters General President Jim Hoffa., ...
(Date:5/16/2008)...broids located just beneath the lining of the uter...ometrial cavity after uterine artery embolization ...according to a new study. , The study included ... examination before and after UAE. The study found...igrated to the endometrial cavity after UAE, said ...
(Date:5/16/2008)...esents Urban Health Institute with 10,000 Sensual ...org at Playboy Mansion Fundraiser, LOS ANGELES, M...hip-hop,and R & B artist J Kwon known best for his...ill be presenting the Urban Health Institute (UHI)...h over $50,000. The donation is,being made to prom...
Breaking Medicine News(10 mins):Health News:Everybody in the Club Scream O! 2
...Medical Journal shows that bacteria with the abili...ble for ear infections can be used successfully an...itis Media is one of the most common bacterial inf...en treated// with large amounts of antibiotics. It...
...isk factor for most cancers, says a Stanford Unive... early in life are more likely to have a genetic c...d and testicular cancers, are even more likey to b....// The model assumed that cancers were the result...
...young women are much more likely to die following ...tradicts the stereotype that men are more likely t...s of Internal Medicine this week. Researchers from...ities followed 6000 patients for two years after t...
...men report higher levels of depression symptoms du...am headed by Dr Jonathan Evans of the University o... out a series of mood questionnaires, following th...ancy through to 8 months after childbirth. The ri...
Other Medicine News:
The Reichert CT200 Tonometer is a perfect match for the XCEL 250 and XCEL 200 slit lamps. It is also compatible with other Zeiss-style slit lamps. It is easily mounted on the top of the slit lamp mic
The SmartPLUG from Medennium is an innovative device used to occlude the "punctum" or tear duct, and conserve the eye's natural tears. SmartPLUG is designed to fit a range of punctum sizes. Made of a
...ons are delivered with a Managed Services approach... upgrades again; utilize our non-proprietary hardw...f your healthcare facility. ,COMBINING RESOUR...d and new equipment; we use the most advanced inte...
GE's complex Cath Lab solution enhances your productivity and workflow efficiency across your department, your facility and your entire enterprise.
Medicine Products: